Checkpoint Capital L.P. Argenx Se Transaction History
Checkpoint Capital L.P.
- $182 Billion
- Q1 2025
A detailed history of Checkpoint Capital L.P. transactions in Argenx Se stock. As of the latest transaction made, Checkpoint Capital L.P. holds 115,000 shares of ARGX stock, worth $65.9 Million. This represents 37.34% of its overall portfolio holdings.
Number of Shares
115,000
Previous 92,500
24.32%
Holding current value
$65.9 Million
Previous $56.9 Billion
19.65%
% of portfolio
37.34%
Previous 28.95%
Shares
5 transactions
Others Institutions Holding ARGX
# of Institutions
498Shares Held
28.5MCall Options Held
330KPut Options Held
286K-
Price T Rowe Associates Inc Baltimore, MD5.38MShares$3.09 Billion0.39% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI2.79MShares$1.6 Billion2.84% of portfolio
-
Janus Henderson Group PLC London, X02.14MShares$1.23 Billion0.73% of portfolio
-
Capital World Investors Los Angeles, CA1.94MShares$1.11 Billion0.19% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.24MShares$708 Million11.83% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $31.7B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...